At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Topicort Topical Spraydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Observational Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) BID in Psoriasis Patients Being Treated With Biologic Agents
Psoriasis Treatment Center of Central New Jersey·interventional·Posted Dec 6, 2016·Updated Mar 20, 2024
In Brief
A Phase 4 clinical trial evaluating Topicort Topical Spray for Psoriasis. Completed, enrolled 20 participants.
Detailed Summary
A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsSun Pharmaceutical Industries, Inc.
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
Primary CompletionSep 2016
Study CompletionOct 2016
First PostedDec 2016
TodayJul 2026
First PostedDec 6, 2016
Enrollment StartMar 1, 2016
Primary CompletionSep 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.6 years ago
Interventions
Topicort Topical Spraydrug
open label Topicort spray